Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.
about
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugsTirapazamine: a novel agent targeting hypoxic tumor cellsTirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia.Tumor-activated prodrugs--a new approach to cancer therapy.Prospects for bioreductive drug development.Tirapazamine-cisplatin: the synergyCisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatinEnhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase.Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells.Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts.Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome.Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.Hypoxia signalling in tumour angiogenesis
P2860
Q26774750-38E4149A-26BC-480E-8A87-7B18E16B06EBQ28302710-A05C9834-8E25-43E7-9FB0-361726E342D8Q34090988-BA931367-9A6B-44E3-A35E-D767B6D28FAEQ35964429-E09E6965-61DE-4913-8F0D-C70184220C04Q36181210-24E93979-8382-4D2D-977F-74BC4CCCFBD7Q36291599-83DA8273-236B-4729-98EE-E7889D954BA5Q36618010-95CE0479-ECA9-41D3-AF5B-8AF75BE338D3Q36618045-A2A1EF79-0659-4F7E-815F-9A37F7546EDCQ36787650-5ACEBAA1-FD31-461F-9733-A73EE78537D7Q37687726-55FAD348-9997-41FD-9112-C4C77CD83D14Q38120850-2F360BD0-82FD-4D44-9095-5F7E754FE72BQ44204636-031E36F2-0AB3-4E1D-886B-F03735562219Q47769995-DC77281F-D2A2-4800-8E40-6019F19EC308Q48109850-17B4346A-B689-400B-BCF5-3FED1C2A9514Q58212136-F4EED44F-11AC-4A6D-9D7A-A3C743A51E64
P2860
Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Phase II study of the combinat ...... ed non-small-cell lung cancer.
@en
Phase II study of the combinat ...... ed non-small-cell lung cancer.
@nl
type
label
Phase II study of the combinat ...... ed non-small-cell lung cancer.
@en
Phase II study of the combinat ...... ed non-small-cell lung cancer.
@nl
prefLabel
Phase II study of the combinat ...... ed non-small-cell lung cancer.
@en
Phase II study of the combinat ...... ed non-small-cell lung cancer.
@nl
P2093
P356
P1433
P1476
Phase II study of the combinat ...... ed non-small-cell lung cancer.
@en
P2093
R T Heelan
R von Roemeling
V A Miller
P304
P356
10.1023/A:1008219125746
P577
1997-12-01T00:00:00Z